Catalyst Wire Dossier Catalyst Wire Dossier

BEVZ92

bevacizumab biosimilar · mAbxience Research S.L.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BEVZ92, covering 2019-07-23 to 2019-07-23. Get the full timeline:

Most recent: Clinical Trial Update: Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients [Phase 1]

See pricing